Reductions in neuropsychiatric symptoms after lecanemab treatment and their associations with imaging markers of β-amyloid clearance

Background: Anti–amyloid-β (Aβ) therapies can slow cognitive decline and reduce cerebral amyloid burden in Alzheimer’s disease (AD). Neuropsychiatric symptoms (NPS) are highly prevalent across the disease course and substantially contribute to disability and caregiver burden. However, whether Aβ cle...

Cijeli opis

Bibliografski detalji

Glavni autori:	Yaping Yan, Daoyan Hu, Linlin Kong, Kaicheng Li, Jun Su, Yingzhe Wu, Hongwei Zhan, Hong Zhang, Yidan Sun, Xiaofeng Dou, Peiyu Huang, Jiong Zhou
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2026-08-01
Serija:	The Journal of Prevention of Alzheimer's Disease
Teme:	Alzheimer’s disease Lecanemab Neuropsychiatric symptoms Aβ clearance
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2274580726001251
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!